Components:
- T: Docetaxel (Taxotere) — a taxane chemotherapy agent
- C: Carboplatin — a platinum-based alkylating agent
- H: Trastuzumab (Herceptin) — a monoclonal antibody targeting HER2 receptor
Indications:
- Used primarily in HER2-positive breast cancer, especially in the adjuvant or neoadjuvant setting for early or locally advanced disease.
- Alternative to anthracycline-based regimens to reduce cardiotoxicity risk.
Mechanism of Action:
- Docetaxel: Stabilizes microtubules, preventing cell division.
- Carboplatin: Causes DNA crosslinks, leading to apoptosis.
- Trastuzumab: Binds HER2 receptor, blocking signaling and inducing antibody-dependent cellular cytotoxicity (ADCC).
Administration:
- Given intravenously every 3 weeks, typically for 6 cycles, with trastuzumab continued for 1 year.
Key Toxicities:
- Docetaxel: Neutropenia, fluid retention, neuropathy, hypersensitivity reactions.
- Carboplatin: Myelosuppression (especially thrombocytopenia), nausea, nephrotoxicity (less than cisplatin).
- Trastuzumab: Cardiotoxicity (monitor LVEF), infusion-related reactions.
Pharmacist Considerations:
- Monitor CBC for cytopenias.
- Cardiac monitoring per trastuzumab protocols.
- Pre-medicate for docetaxel hypersensitivity and fluid retention.
- Educate patients on side effects and adherence to trastuzumab therapy.